A detailed history of Northern Trust Corp transactions in Bio Atla, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 88,781 shares of BCAB stock, worth $142,937. This represents 0.0% of its overall portfolio holdings.

Number of Shares
88,781
Previous 327,544 72.89%
Holding current value
$142,937
Previous $448,000 65.18%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.17 - $2.05 $279,352 - $489,464
-238,763 Reduced 72.89%
88,781 $156,000
Q2 2024

Aug 14, 2024

SELL
$1.37 - $3.92 $36,162 - $103,472
-26,396 Reduced 7.46%
327,544 $448,000
Q1 2024

May 14, 2024

SELL
$1.88 - $3.46 $3,673 - $6,760
-1,954 Reduced 0.55%
353,940 $1.22 Million
Q4 2023

Feb 13, 2024

SELL
$1.27 - $3.18 $1,861 - $4,661
-1,466 Reduced 0.41%
355,894 $875,000
Q3 2023

Nov 13, 2023

SELL
$1.7 - $3.07 $12,610 - $22,773
-7,418 Reduced 2.03%
357,360 $607,000
Q2 2023

Aug 11, 2023

BUY
$2.83 - $3.87 $776,486 - $1.06 Million
274,377 Added 303.51%
364,778 $1.09 Million
Q1 2023

May 15, 2023

BUY
$2.3 - $8.25 $11,541 - $41,398
5,018 Added 5.88%
90,401 $242,000
Q4 2022

Feb 13, 2023

BUY
$6.29 - $11.01 $85,091 - $148,943
13,528 Added 18.83%
85,383 $704,000
Q3 2022

Nov 14, 2022

BUY
$2.94 - $11.87 $53,131 - $214,514
18,072 Added 33.6%
71,855 $553,000
Q2 2022

Aug 12, 2022

SELL
$2.13 - $5.38 $256,213 - $647,149
-120,288 Reduced 69.1%
53,783 $153,000
Q1 2022

May 13, 2022

SELL
$4.38 - $18.78 $26,179 - $112,248
-5,977 Reduced 3.32%
174,071 $871,000
Q4 2021

Feb 08, 2022

BUY
$19.0 - $30.95 $73,112 - $119,095
3,848 Added 2.18%
180,048 $3.54 Million
Q3 2021

Nov 15, 2021

BUY
$29.44 - $43.74 $855,173 - $1.27 Million
29,048 Added 19.74%
176,200 $5.19 Million
Q2 2021

Aug 13, 2021

BUY
$38.07 - $56.17 $929,364 - $1.37 Million
24,412 Added 19.89%
147,152 $6.24 Million
Q1 2021

May 12, 2021

BUY
$32.41 - $70.91 $3.98 Million - $8.7 Million
122,740 New
122,740 $6.24 Million

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $58.4M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.